This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • Wegovy (semaglutide 2.4 mg), the first and only on...

Wegovy (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US.-Novo Nordisk

Read time: 1 mins
Published:6th Jun 2021
Novo Nordisk announced that the FDA has approved Wegovy (the brand name for once-weekly semaglutide 2.4 mg injection in the US) for chronic weight management. Wegovy is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity (initial BMI greater than 30 kg/m2) or overweight (initial BMI greater than 27 kg/m2) with at least one weight-related comorbidity.

 Wegovy is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management for people living with obesity. The approval is based on the results from the STEP phase IIIa clinical trial programme. Across the trials in people without type 2 diabetes, an average weight loss of 17-18% sustained over 68 weeks was reported for people with obesity treated with Wegovy. Wegovy demonstrated a safe and well-tolerated profile across the programme, with the most common adverse events being gastrointestinal. Novo Nordisk expects to launch Wegovy in the United States later in June 2021.

Condition: Obesity
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.